Covidien Plc: (NYSE: COV)
$65.80
0.26 (0.40%)
Volume 2,975,452
May 21 04:00 PM ET
Zacks Rank: 5-Strong Sell 
| #5 |
Overview Quote
Stock Activity
| Day Low - High | 65.56 - 66.08 |
| 52wk Low - High | 50.25 - 68.83 |
| Previous Close | 65.54 |
| Avg. Volume | 3,622,204 |
| Industry | MED PRODUCTS |
| Market Cap | 31.06 B |
| Div - Yield | 1.04 - 1.58 |
| Beta | 0.88 |
| PE (Forward) | 17.80 |
| Current Year Est. | 3.70 |
| Quarterly Earnings ESP |
0.00% |
Premium research
Zacks Rank
|
 5 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
177 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | 17.80 |
| PEG Ratio | 1.86 |
| Current Year Est. | 3.70 |
| Current Quarter Estimate | 0.90 |
| Most Accurate Estimate | 0.90 |
| Earnings ESP |
0.00% |
| Next Earnings Report Date | 07-25-2013 |
| EPS Last Year | 4.31 |
| Expected Earnings Growth | 9.56% |
Company Description
Covidien PLC, formerly Covidien Ltd, is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. It operates its business through four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products and Medical Supplies. The Medical Devices segment includes the development, manufacture and sale of endomechanical, soft tissue repair, energy, oximetry and monitoring, airway and ventilation, vascular, SharpSafety and clinical care products; Imaging Solutions, which includes the development, manufacture and marketing of radiopharmaceuticals and contrast products; Pharmaceutical Products, which includes the development, manufacture and distribution of dosage pharmaceuticals and active pharmaceutical ingredients, and Medical Supplies, which includes the development, manufacture and sale of nursing care products, medical surgical products and original equipment manufacturer products.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (09/2013) |
Next Year (09/2014) |
|
|---|---|---|---|---|
| Average Estimate | 0.90 | 0.92 | 3.70 | 4.06 |
| Number of Estimates | 7 | 7 | 12 | 10 |
| Low Estimate | 0.88 | 0.89 | 3.67 | 4.00 |
| High Estimate | 0.93 | 0.94 | 3.73 | NA |
| Year Ago EPS | 1.07 | 1.02 | 4.07 | 3.70 |
| EPS Growth | -16.02% | -10.22% | -9.17% | 9.86% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| COVIDIEN PLC | COV | 65.80 | |
|
| CONCEPTUS INC | CPTS | 30.98 | |
|
| ATRICURE INC | ATRC | 8.99 | |
|
| INVIVO THERAPT | NVIV | 2.90 | |
|
| TRANS1 INC | TSON | 1.59 | |
|
| ABAXIS INC | ABAX | 44.22 | |
|
| ADVAXIS INC | ADXS | 0.05 | |
|
| BAXTER INTL | BAX | 73.04 | |
|
| BIO-RAD LABS -A | BIO | 116.12 | |
|
| BIOLIFE SOL INC | BLFS | 0.38 | |
|
Sector:Medical>> Industry:MED PRODUCTS
COMPARE TICKER vs. Its Peers
Zacks Commentary
FDA Nod for COV's Advanced Nellcor
May 21, 2013
Covidien Prices Senior Notes
May 16, 2013
Masimo Wins a Major Turkish Client
May 13, 2013
Covidien Provides 2013 Outlook
May 06, 2013
Masimo Matches Earnings Est.
May 03, 2013
Company News for April 29, 2013
Apr 29, 2013
Covidien's 2Q Earnings Beat
Apr 26, 2013
The Zacks Analyst Blog Highlights: Covidien, Central Garden & Pet, Wal-Mart Stores, Home Depot and Jarden
Apr 25, 2013
Financials
| EPS TTM | 4.31 |
| Sales | 11,852 |
| Net Income | 1,846 |
| Price/Earnings | 15.27 |
| Price/Book | 2.83 |
| Price/Cash Flow | 12.10 |
| Price/Sales | 2.55 |
News
Covidien Announces Clinical Trial Data Showing Endoscopic Ablation Therapy Eliminates Precancerous Esophageal Tissue and Significantly Reduces Disease Progression - Businesswire
May 22, 2013
Covidien Says Trial Data for Endoscopic Ablation Therapy Shows Elimination of Precancerous Esophageal Tissue, Significantly Cut Disease Progression - Benzinga
May 22, 2013
Covidien awarded FDA 510(k) Clearance for Nellcor pulse oximetry motion claims - M2
May 21, 2013
Covidien's Technology Platform to Diagnose Early Lung Cancer Part of New Guidelines of American College of Chest Physicians - Businesswire
May 21, 2013
Covidien (COV) Showing Bullish Technicals But Could Fall Through $65.21 Support - Freshbrewedmedia
May 20, 2013
Covidien Receives FDA 510(k) Clearance for Nellcor(TM) Pulse Oximetry Motion Claims - Businesswire
May 20, 2013
WEALTHMAKERS.COM Issues Bearish Research Reports on COV, PYK - M2
May 17, 2013
Covalon Proposes Share Consolidation - Cnw Group
May 16, 2013
Broker Recommendations
| Current ABR | 1.28 |
| ABR (Last Week) | 1.28 |
| # of recs in ABR | 16 |
| Average Target Price | 70.50 |
| Industry Rank by ABR | 177 out of 265 |
| Rank in Industry | 72 out of 73 |
